Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer

Marketwired December 12, 2014

HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system

PR Newswire December 12, 2014

8th Annual OneMedForum San Francisco, 1/12-13/15, Announces First Group of Presenting Companies

Business Wire December 12, 2014

Epizyme Elects Kenneth Bate to Board of Directors

Business Wire December 12, 2014

BioTime to Host Investor and Analyst Day on December 15, 2014

Business Wire December 12, 2014

Macrophage Therapeutics to Present Data Supporting Potential for Breakthrough with Manocept(TM) in Immunotherapy

Business Wire December 12, 2014

Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium

PR Newswire December 12, 2014

Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease

PR Newswire December 12, 2014

China Human Vaccine Industry Report, 2014-2017

PR Newswire December 12, 2014

Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium

Business Wire December 12, 2014

Plandai Biotechnology, Inc. Receives Halaal Certification for Senteeko Facility

Marketwired December 12, 2014

Pharmacyclics Named 2014 Outstanding Company by BayBio

PR Newswire December 12, 2014

Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber

PR Newswire December 12, 2014

Melanoma Drugs Market Forecast 2014-2024

PR Newswire December 12, 2014

Research and Markets: India Non-Vascular Stents Market Outlook to 2020: Key players covered include Boston Scientific, Taewoong, Merit, Cook, PNN, Teleflex and C.R. Bard

Business Wire December 12, 2014

Research and Markets: Germany Non-Vascular Stents Market Outlook to 2020: Key players covered include Boston, Taewoong, Merit, Cook, PNN, Teleflex and C.R. Bard

Business Wire December 12, 2014

Research and Markets: Germany Gynecological Devices Market Outlook to 2020: Key players covered include Bayer, Hologic, Boston Scientific, Microsulis, Cook and Merit

Business Wire December 12, 2014

Research and Markets: Brazil Non-Vascular Stents Market Outlook to 2020: Key players covered include Boston Scientific, Taewoong, Merit, Cook, PNN, Teleflex and C.R. Bard

Business Wire December 12, 2014

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS

Thomson Reuters ONE December 12, 2014

Immunomedics Reports Expanded Phase 1/2 Trials Confirm Activity and Good Safety Profile of Sacituzumab Govitecan (Immu-132) in Patients With Advanced Triple-Negative Breast Cancer

GlobeNewswire December 12, 2014